Article
Immunology
Caroline Carle, Francoise Fortenfant, Marie Tauber, Emilie Tournier, Carle Paul, Chloe Bost, Yves Renaudineau
Summary: The lupus band test is debated for its ability to distinguish between cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), and its association with antinuclear antibodies (ANA) and complement reduction. Certain clinical, histopathologic, and serological parameters can effectively differentiate lupus from other skin disorders and distinguish between SLE and CLE.
CLINICAL IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Masahiro Ayano, Takahiko Horiuchi
Summary: Systemic lupus erythematosus (SLE) is a disease where complement is crucial in its pathogenesis. Complement levels in blood and histological tests are used for SLE management, and the evaluation of complement status is useful for diagnosis, disease activity assessment, treatment response prediction, and prognosis. Novel complement biomarkers are more sensitive than traditional markers and have wider application. This review summarizes the utility of complement testing in SLE management over the last decade.
Article
Immunology
Massimo Radin, Irene Cecchi, Francesca Crisafulli, Evandro Mendes Klumb, Guilherme Ramires de Jesus, Marcela Ignacchiti Lacerda, Miguel Angel Saavedra, Geraldine Vanessa Reyes-Navarro, Luca Iaccarino, Maddalena Larosa, Gabriella Moroni, Francesco Tamborini, Dario Roccatello, Laura Andreoli, Savino Sciascia, Cecilia Beatrice Chighizola
Summary: A network meta-analysis of 19 studies found that complement levels, specifically C3 and C4, gradually increased during gestation in lupus pregnant women. However, patients with lupus nephritis and gestational flares had significantly lower complement levels at all timepoints. Particularly in early gestation, a reduction or smaller increase in C3 and C4 levels, even within the normal range, may predict gestational flares.
AUTOIMMUNITY REVIEWS
(2023)
Article
Medicine, General & Internal
Ana Maria Gheorghiu, Cristina Vrancianu, Iuliana Conea, Aida Boca, Madalina Bolboceanu, Cristiana Draganescu, Mihai Bojinca, Ioan Ancuta
Summary: Through retrospective analysis, the study found that the 2019 ACR/EULAR criteria showed good sensitivity in identifying early SLE, and its sensitivity remained high in patients with a short disease duration. Although its specificity was slightly lower than other criteria, it still had high value.
Article
Immunology
Jessica S. Kleer, Pascal A. Rabatscher, Jessica Weiss, Joel Leonardi, Severin B. Vogt, Andrea Kieninger-Grafitsch, Carlo Chizzolini, Uyen Huynh-Do, Camillo Ribi, Marten Trendelenburg
Summary: The study found that epitope-specific anti-C1q in SLE patients is associated with specific disease manifestations, providing more diagnostic value than conventional anti-C1q.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Maria Garcia-Gonzalez, Fuensanta Gomez-Bernal, Juan C. C. Quevedo-Abeledo, Yolanda Fernandez-Cladera, Agustin F. Gonzalez-Rivero, Antonia de Vera-Gonzalez, Inigo de la Rua-figueroa, Raquel Lopez-Mejias, Federico Diaz-Gonzalez, Miguel A. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: This study assessed the function of the three complement pathways in SLE patients and found that AL and LE pathways had lower functional values compared to the CL pathway. Clinical activity was not related to functional values of the C pathways, but increased DNA binding was negatively associated. Disease damage was positively correlated with C pathways and components. Anti-ribosomes and anti-nucleosomes antibodies showed a higher relationship with C activation, mainly through the LE and CL pathways. IgG anti-beta 2GP antibodies were most closely related to C activation, predominantly involving the AL pathway.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Fengping Liu, Tianli Ren, Xiaodi Li, Qixiao Zhai, Xifeng Xu, Nan Zhang, Peng Jiang, Yaofang Niu, Longxian Lv, GuoXun Shi, Ninghan Feng
Summary: The microbiome alterations in the gut and oral cavity are associated with the development of systemic lupus erythematosus (SLE). Research on 35 SLE patients revealed reduced bacterial richness and diversity in feces, and increased bacterial diversity in saliva. These findings suggest that different body niches in SLE patients have distinct bacterial profiles that may play a role in the disease development.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Maria Garcia-Gonzalez, Fuensanta Gomez-Bernal, Juan C. Quevedo-Abeledo, Yolanda Fernandez-Cladera, Agustin F. Gonzalez-Rivero, Raquel Lopez-Mejias, Federico Diaz-Gonzalez, Miguel a. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: This study analyzed the relationship between the complement (C) system and cholesterol efflux capacity (CEC) in patients with systemic lupus erythematosus (SLE). The study found that there is an interconnected relationship between the C system and CEC in patients with SLE.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Wentian Lu, Fengmei Tian, Jinlu Ma, Ying Zhong, Zhichun Liu, Leixi Xue
Summary: The diagnostic performance of ACR-1997, SLICC-2012, and EULAR/ACR-2019 classification criteria in adult patients with systemic lupus erythematosus (SLE) was evaluated. The results showed that SLICC-2012 and EULAR/ACR-2019 had better diagnostic ability than ACR-1997, and the sensitivity of the former two criteria was also higher than that of the latter.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Aleida Susana Castellanos Gutierrez, Francesc Figueras, Diana M. Morales-Prieto, Ekkehard Schleussner, Gerard Espinosa, Nuria Banos
Summary: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects women of childbearing age. During pregnancy, SLE is associated with a higher risk of perinatal morbidity and mortality. Several studies have suggested that placental dysfunction may play a crucial role in this association.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Brandon C. H. Tan, Isaac Tang, Julie Bonin, Rachel Koelmeyer, Alberta Hoi
Summary: This study evaluated the performance of new classification criteria for systemic lupus erythematosus (SLE) in a real-world rheumatology department. The results showed that the sensitivity and specificity of each set of criteria varied slightly, with SLICC 2012 and SLERPI 2020 having the highest sensitivities and ACR 1997 having the highest specificity. All classification criteria serve as good instructional aids for clinicians to understand SLE manifestations.
Review
Medicine, General & Internal
Manuel F. Ugarte-Gil, Yurilis Fuentes-Silva, Victor R. Pimentel-Quiroz, Guillermo J. Pons-Estel, Rosana Quintana, Bernardo A. Pons-Estel, Graciela S. Alarcon
Summary: Systemic lupus erythematosus (SLE) has a more severe impact on non-White populations due to their genetic background and sociodemographic characteristics. Studies on Latin American SLE patients have provided insights into their genetic and clinical characteristics as well as prognostic factors, guiding treatment guidelines and supporting regional and global projects. Educational activities in Spanish and Portuguese have also been initiated to improve patients' health literacy. Despite lower research output, studies from the region and the networks developed have the potential to serve as a model for other rare autoimmune diseases.
FRONTIERS IN MEDICINE
(2023)
Article
Medical Laboratory Technology
Jian-Jun Huang, Tong-Jun Mao, Zi-Yu Zhang, Gang Feng
Summary: The study investigates the role of lymphocyte-bound C4d and immunoglobulins in the diagnosis and monitoring of SLE. The levels of C4d and Igs were measured in SLE patients, patients with other inflammatory diseases, and healthy individuals. The results suggest that LB-C4d/Igs could be used as reliable indicators for SLE diagnosis and activity monitoring.
CLINICAL BIOCHEMISTRY
(2023)
Article
Hematology
Leda Coelewij, Kirsty E. Waddington, George A. Robinson, Elvira Chocano, Thomas McDonnell, Filipa Farinha, Junjie Peng, Pierre Donnes, Edward Smith, Sara Croca, Jyoti Bakshi, Maura Griffin, Andrew Nicolaides, Anisur Rahman, Elizabeth C. Jury, Ines Pineda-Torra
Summary: This study found that patients with SLE have global changes in their lipoprotein profiles, but standard serum lipid measurements cannot accurately predict their risk of cardiovascular disease. Serum metabolites may be promising biomarkers to uncover the multi-metabolic phenotypes of subclinical atherosclerosis in SLE patients.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Review
Immunology
Marten Trendelenburg
Summary: This review discusses the mechanisms and importance of anti-C1q in the development of SLE, highlighting the potential role of C1q in the inflammatory process and exploring its clinical application as a biomarker.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Article
Rheumatology
Sindhu R. Johnson, Dafna D. Gladman, Hermine Brunner, David Isenberg, Ann E. Clarke, Megan R. W. Barber, Laurent Arnaud, Paul R. Fortin, Marta Mosca, Alexandre E. Voskuyl, Susan Manzi, Cynthia Aranow, Anca Askanase, Graciela S. Alarcon, Sang-Cheol Bae, Nathalie Costedoat-Chalumeau, Jessica A. English, Guillermo J. Pons-Estel, Bernardo A. Pons-Estel, Rebecca Gilman, Ellen M. Ginzler, John G. Hanly, Soren Jacobsen, Kenneth Kalunian, Diane L. Kamen, Chynace Lambalgen, Alexandra Legge, S. Sam Lim, Anselm Mak, Eric F. Morand, Christine A. Peschken, Michelle Petri, Anisur Rahman, Rosalind Ramsey-Goldman, John A. Reynolds, Juanita Romero-Diaz, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Elisabet Svenungsson, Zahi Touma, Murray Urowitz, Evelyne Vinet, Ronald F. van Vollenhoven, Heather Waldhauser, Daniel J. Wallace, Asad Zoma, Ian N. Bruce
Summary: The SLICC, ACR, and Lupus Foundation of America are developing a revised SLE damage index (SDI) due to shifts in the concept of damage in SLE. A qualitative study was conducted to evaluate contemporary constructs in SLE damage and develop a conceptual framework for the revised SDI.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Immunology
Savino Sciascia, Rory Bloch, Tyler O'Malley, Anja Kammesheidt, Roberta Vezza Alexander
Summary: High titers of aPL often remain positive, allowing for earlier diagnosis and risk assessment at the initial screening. Low titers may require retesting. There is a high correlation between aCL and aB2GP1 measured using two different technologies. The correlation between PC4d and aPL is low to moderate, suggesting a possible additional value in evaluating the association with thrombosis in autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Cristina Arriens, Y. K. Onno Teng, Ellen M. Ginzler, Samir V. Parikh, Anca D. Askanase, Amit Saxena, Keisha Gibson, Dawn J. Caster, Tatsuya Atsumi, Laura Lisk, Simrat Randhawa, Rashieda Gluck, Neil Solomons, Robert B. Huizinga
Summary: This integrated analysis evaluates the efficacy and safety of voclosporin in the treatment of lupus nephritis. The study found that voclosporin, in combination with mycophenolate mofetil and oral glucocorticoids, significantly improved renal response compared to control, with similar incidence of adverse events. The results confirm the effectiveness and safety of voclosporin across diverse racial and ethnic groups.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Ann E. Clarke, John G. Hanly, Murray B. Urowitz, Yvan St. Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Vernon Farewell
Summary: The objective of this study was to estimate the costs associated with neuropsychiatric events in SLE. The study found that new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs. Indirect costs exceeded direct costs by 3.0 to 5.2 fold.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Kenneth C. Kalunian, Richard Furie, Eric F. Morand, Ian N. Bruce, Susan Manzi, Yoshiya Tanaka, Kevin Winthrop, Ihor Hupka, Lijin Jinny Zhang, Shanti Werther, Gabriel Abreu, Micki Hultquist, Raj Tummala, Catharina Lindholm, Hussein Al-Mossawi
Summary: This study investigates the long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE). The results show that anifrolumab is well-tolerated and has a favorable benefit-risk profile in patients with moderate-to-severe SLE receiving standard therapy.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Celline C. Almeida-Brasil, John G. Hanly, Murray Urowitz, Ann Elaine Clarke, Guillermo Ruiz-Irastorza, Caroline Gordon, Rosalind Ramsey-Goldman, Michelle A. Petri, Ellen M. Ginzler, Daniel J. Wallace, Sang-Cheol Bae, Juanita Romero-Diaz, Mary-Anne Dooley, Christine Peschken, David Isenberg, Anisur Rahman, Susan Manzi, Soren Jacobsen, S. Sam Lim, Ronald van Vollenhoven, Ola Nived, Andreas Joensen, Diane L. Kamen, Cynthia Aranow, Jorge Sanchez-Guerrero, Dafna D. Gladman, Paul R. Fortin, Graciela S. Alarcon, Joan T. Merrill, Kenneth Kalunian, Manuel Ramos-Casals, Kristjan Steinsson, A. Zoma, Anca D. Askanase, Munther Khamashta, Ian N. Bruce, Murat Inanc, Luck Lukusa, Sasha Bernatsky
Summary: This study evaluates hydroxychloroquine (HCQ)-related retinal toxicity in patients with newly diagnosed systemic lupus erythematosus (SLE). The study found no cases of retinopathy within the first four years of HCQ use. Cumulative HCQ use may be associated with an increased risk of retinal toxicity. Therefore, ophthalmology monitoring remains important, especially in patients using HCQ for a long duration, requiring higher doses, and diagnosed with SLE at an older age.
LUPUS SCIENCE & MEDICINE
(2022)
Article
Rheumatology
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader
Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Michelle Petri, Ian N. Bruce, Thomas Doerner, Yoshiya Tanaka, Eric F. Morand, Kenneth C. Kalunian, Mario H. Cardiel, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J. McVeigh, Marta Mosca
Summary: Baricitinib, an oral inhibitor of Janus kinase 1 and 2, was evaluated as a treatment for patients with systemic lupus erythematosus (SLE) in a 52-week phase 3 study. The study found that baricitinib did not significantly improve SLE disease activity compared with placebo, and there were no new safety concerns.
Article
Rheumatology
Joy Buie, Lauren Bloch, Eric F. Morand, Ronald F. van Vollenhoven, Victoria P. Werth, Zahi Touma, Peter Lipsky, Kenneth Kalunian, Anca D. Askanase, L. Ines, Christopher Reed, MaryBeth Son, Timothy Franson, Karen Costenbader, Laura Eve Schanberg
Summary: Drug development in lupus has improved but lags behind other rheumatic diseases. Challenges in assessing lupus therapies include disease heterogeneity, study design limitations, and lack of validated biomarkers impacting regulatory decision-making. The meeting report addresses the need for standardized outcome measures to accelerate lupus therapeutics development and highlights ongoing efforts in outcome measure development.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Rheumatology
Rashmi Dhital, Monica Guma, Dilli R. Poudel, Christina Chambers, Kenneth Kalunian
Summary: Care of young adults with SLE is challenging due to major life transitions co-occurring with chronic healthcare needs. This study found that young adults with SLE had higher rates of serious infection-related hospitalization compared to adults with SLE and young adults without SLE. Race/ethnicity and comorbidities were associated with hospitalization in young adults with SLE.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Rheumatology
Yann Nguyen, Benoit Blanchet, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Joensen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Veronique Le Guern, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Nathalie Costedoat-Chalumeau
Summary: The study aimed to assess the association between severe nonadherence to hydroxychloroquine (HCQ), analyzed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates. Severe nonadherence was found to be independently associated with increased risk of SLE flares, early damage, and five-year mortality.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Amit Saxena, Ellen M. Ginzler, Keisha Gibson, Bancha Satirapoj, Adolfina Elizabeth Zuta Santillan, Olena Levchenko, Sandra Navarra, Tatsuya Atsumi, Shinsuke Yasuda, Nilmo Noel Chavez-Perez, Cristina Arriens, Samir V. Parikh, Dawn J. Caster, Vanessa Birardi, Simrat Randhawa, Laura Lisk, Robert B. Huizinga, Y. K. Onno Teng
Summary: This study evaluated the long-term safety and efficacy of voclosporin in patients with lupus nephritis. The results showed that voclosporin treatment was well tolerated and led to improved renal response and reduced proteinuria over a three-year period.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Health Care Sciences & Services
Maria Dall'Era, Kenneth Kalunian, Michael Eaddy, Augustina Ogbonnaya, Eileen Farrelly, Eric Turowski, Vanessa Birardi, Neil Solomons, Simrat Randhawa, Paola Mina-Osorio
Summary: This study aimed to evaluate treatment utilization and health care costs associated with active disease, low disease activity, and end-stage renal disease (ESRD) in patients with lupus nephritis (LN). The results showed that the treatment burden and costs were high for patients with active disease and ESRD, and treatments that allow patients to achieve and maintain low disease activity may help improve patient outcomes and reduce overall health care costs.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
(2023)
Article
Health Care Sciences & Services
Tyler O'Malley, Fenglong Xie, Yujie Su, Cassie Clinton, Debra J. Zack, Chung Haechung, Michael Grabner, Jeffrey R. Curtis
Summary: The study compared the clinical utility of a new muttianatyte assay panel with traditional auto antibodies for the diagnosis and treatment of SLE. It found that patients who tested positive with AVISE were more likely to be diagnosed with SLE and initiate treatment, while AVISE negative patients had a greater decrease in outpatient laboratory testing posttest relative to tANA negative patients.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
(2022)
Article
Rheumatology
Vibeke Strand, Sean O'Quinn, Richard A. Furie, Eric F. Morand, Kenneth C. Kalunian, Erik G. Schwetje, Gabriel Abreu, Raj Tummala
Summary: BICLA responders showed significant and clinically meaningful improvements in Patient Global Assessment, health-related quality of life, fatigue, and pain compared to BICLA non-responders. More patients with moderate to severe SLE who received anifrolumab were BICLA responders and experienced improved health-related quality of life, fatigue, and pain compared to those who received placebo.
LANCET RHEUMATOLOGY
(2022)